JAK2 inhibitor demonstrates effective, durable control of myelofibrosis
Monday, December 7, 2009 - 09:42
in Health & Medicine
A first-in-its class oral medication provides significant and durable relief for patients with a rare, debilitating and lethal bone marrow disorder called myelofibrosis, researchers at The University of Texas M. D. Anderson Cancer Center reported today at the 51st Annual Meeting of the American Society of Hematology.